CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
3.400
+0.130 (3.98%)
At close: Jun 26, 2026, 4:00 PM EDT
3.390
-0.010 (-0.29%)
After-hours: Jun 26, 2026, 6:36 PM EDT
CytomX Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for CytomX Therapeutics stock have an average target of 12.33, with a low estimate of 6.00 and a high estimate of 16. The average target predicts an increase of 262.65% from the current stock price of 3.40.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CytomX Therapeutics stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 6 | 6 | 6 | 5 |
| Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Hold | 2 | 2 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 9 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Reiterates $11 | Buy | Reiterates | $11 | +223.53% | Jun 4, 2026 |
| Wolfe Research | Wolfe Research | Buy Initiates $6 | Buy | Initiates | $6 | +76.47% | May 19, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $17 → $11 | Buy | Maintains | $17 → $11 | +223.53% | May 11, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $12 | Buy | Reiterates | $12 | +252.94% | May 8, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $15 | Buy | Maintains | $15 | +341.18% | May 8, 2026 |
Financial Forecast
Revenue This Year
35.75M
from 76.20M
Decreased by -53.09%
Revenue Next Year
34.26M
from 35.75M
Decreased by -4.17%
EPS This Year
-0.42
from -0.15
EPS Next Year
-0.49
from -0.42
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 80.0M | 84.7M | |
| Avg | 35.7M | 34.3M | |
| Low | 10.3M | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 5.0% | 137.0% | |
| Avg | -53.1% | -4.2% | |
| Low | -86.5% | -100.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.34 | -0.25 | |
| Avg | -0.42 | -0.49 | |
| Low | -0.51 | -0.81 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.